Hell hath no fury like Icahn scorned. Frustrated by Biogen Idec's decision to take itself off the market [1], Carl Icahn (photo [2]) is now accusing the biotech giant of lying about its prospective buyers. Icahn says Biogen Idec's documents filed with the SEC are full of "inconsistencies" and "untruths." Contradicting the SEC documents, Icahn's group says that the company's board had little input in the sales process and rejected the company's claim that it did not stand in the way of talks with its drug partner Elan.
"It appears at least one potential bidder was denied its request to talk to Elan before submitting a binding offer, which may have caused that bidder to walk away from the process," states Icahn's filing.
- check out the AFX story [3]
Related Articles:
Biogen squares off against Icahn in board battle [4]
Icahn aims for Biogen control [5]
Biogen shares deflate as it gives up on sale [1]
What's Biogen Idec really worth to Big Pharma? [6]
Biogen Idec in play after Icahn makes his move [7]
Links:
[1] http://www.fiercebiotech.com/story/biogen-shares-deflate-it-gives-sale/2007-12-13
[2] http://www.fiercebiotech.com/story/carl-icahn/2007-10-15
[3] http://www.forbes.com/afxnewslimited/feeds/afx/2008/06/05/afx5084043.html
[4] http://www.fiercebiotech.com/story/biogen-squares-off-against-icahn-in-board-battle/2008-04-18
[5] http://www.fiercebiotech.com/story/icahn-aims-biogen-control/2008-01-29
[6] http://www.fiercebiotech.com/story/whats-biogen-idec-really-worth-big-pharma/2007-10-29
[7] http://www.fiercebiotech.com/story/biogen-idec-play-after-icahn-makes-his-move/2007-10-15